A San Francisco-based biopharma company developing a topical protein therapy for dystrophic epidermolysis bullosa (DEB).

US pharma giant Merck & Co has started building a $1 billion, 470,000-square-foot biologics center of excellence in ...

US biotech firm Stealth BioTherapeutics (OTCQB: MITO) is facing renewed uncertainty after the American medicines regulator ...

US biotech Transneural Therapeutics has named industry veteran Mark Demitrack as its chief research and development officer, ...

Regulus Therapeutics (Nasdaq: RGLS) saw its shares leap 133% to $7.84 in pre-market activity this morning, on the news it has ...

Chicago-based drugmaker AbbVie has announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), ...

Danish drugmaker Novo Nordisk has announced that it is expanding patient access to Wegovy (semaglutide) injection 2.4 mg in ...

Swiss generics and biosimilars major Sandoz (SIX: SDZ) has signed a global collaboration with Shanghai Henlius Biotech (HKEX: ...

California-based Creyon Bio has announced a global licensing and multi-target research collaboration with US pharma major Eli ...

The Russian pharmaceutical market grew up to 814 billion roubles ($10 billion) in the first quarter of 2025, 11% higher ...

Swiss generics and biosimilars major Sandoz (SIX: SDZ) today presented its net sales update for the first quarter of 2025.

The US Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also ...